]>
IRCT20111224008507N3 IRCT 2020-06-27 Mazandaran University of Medical Sciences Evaluation of the effect of Ivermectin in the treatment of coronavirus infection Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020 2020-05-21 anticipated 60 Complete https://irct.ir/trial/49174 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly assigned to two groups of intervention and control with 33 members using block randomization with block sizes of 4. Randomization will be done using the software randomization option in Excel. The randomization process is performed by the study methodology consultant and clinical researchers are not aware of the randomization process, Blinding description: After selecting the samples, none of the participant will be aware of randomization and allocation to groups. The evaluator nurse of data recording is from out of the study and questionnaires will be provided in the form of coding to him/her. So, the present study is double-blinded. 3 COVID-19 infection. Intervention 1: Control group: In the control group, only standard drugs of the national protocol are used. Intervention 2: Intervention group: In the intervention group, along with the standard drugs of the national protocol, a single dose of 3 mg Ivermectin oral tablet with a dose of 0.2 mg/kg of Tadbir Kala Jam Company will be used according to the following table: weight 15-24, 3 mg; Weight 25-35, 6 mg; Weight 36-50, 9 mg; Weight 51-80, 12 mg and weight over 80, 0.2 mg/kg. Yes - There is a plan to make this available What will be shared: Part of the data is available When: Starting in January 2021 To whom: All people Conditions: Nothing Where to obtain: Contact Dr. Mohammad Sadegh Rezai. E-mail: drmsrezaii@yahoo.com How to obtain: After contact, information is sent within a few days Comments:
public Dr. Mohammad Sadegh Rezai
Bouali Hospital, Pasdaran boulevard, Sari
Sari Iran (Islamic Republic of) 4815838477 +98 11 3334 2334 drmsrezaii@yahoo.com Mazandaran University of Medical Sciences scientific Mohammadsadegh Rezai
Bouali Hospital, Pasdaran Boulevard, Sari
Sari Iran (Islamic Republic of) 4815838477 +98 11 3334 2334 drmsrezaii@yahoo.com Mazandaran University of Medical Sciences Iran (Islamic Republic of) Patients hospitalized with suspected Covid-19 Informed consent for inclusion in study Age above 5 years Weight above 15 kg 5 years no limit Both Liver and kidney disease Patients with acquired immunodeficiency Consumption of warfarin and ACEI family drugs (captopril, enalapril, etc.) Breastfeeding B34.2 Coronavirus infection, unspecified Treatment - Drugs Treatment - Drugs Control group: In the control group, only standard drugs of the national protocol are used. Intervention group: In the intervention group, along with the standard drugs of the national protocol, a single dose of 3 mg Ivermectin oral tablet with a dose of 0.2 mg/kg of Tadbir Kala Jam Company will be used according to the following table: weight 15-24, 3 mg; Weight 25-35, 6 mg; Weight 36-50, 9 mg; Weight 51-80, 12 mg and weight over 80, 0.2 mg/kg Clinical symptoms including fever, chills, sore throat, cough, shortness of breath, decreased appetite, abdominal pain, dizziness, insomnia, itching, joint pain, joint swelling, headache, nausea, vomiting, diarrhea, malaise, conjunctivitis, tachycardia, wheezing, rhonchus, retraction, hypotension, rash, other symptoms. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Observation and record in checklist. Respiratory rate and O2 saturation. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Pulse Oximeter. Mazandaran University of Medical Sciences Approved 2020-04-11 Ethics committee of Mazandaran University of Medical Sciences Vice chancellor for Research, Moallem square, Sari Sari Mazandaran Iran (Islamic Republic of)